Tetra Bio-Pharma’s PPP002 on Track After Type C Meeting with FDA
Tetra Bio-Pharma Inc. today announced it received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™ mucoadhesive product.